KR20050094461A - A therapeutic composition for the treatment of hiv-1 and hiv-2 - Google Patents
A therapeutic composition for the treatment of hiv-1 and hiv-2 Download PDFInfo
- Publication number
- KR20050094461A KR20050094461A KR1020057013692A KR20057013692A KR20050094461A KR 20050094461 A KR20050094461 A KR 20050094461A KR 1020057013692 A KR1020057013692 A KR 1020057013692A KR 20057013692 A KR20057013692 A KR 20057013692A KR 20050094461 A KR20050094461 A KR 20050094461A
- Authority
- KR
- South Korea
- Prior art keywords
- amount
- present
- potassium iodide
- nimodipine
- inulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 230000001225 therapeutic effect Effects 0.000 title claims description 17
- 238000000034 method Methods 0.000 claims abstract description 39
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 33
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract description 32
- 230000009385 viral infection Effects 0.000 claims abstract description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 287
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 70
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 51
- 229920001202 Inulin Polymers 0.000 claims description 51
- 229910052804 chromium Inorganic materials 0.000 claims description 51
- 239000011651 chromium Substances 0.000 claims description 51
- 229940029339 inulin Drugs 0.000 claims description 51
- 229960000715 nimodipine Drugs 0.000 claims description 51
- 239000011701 zinc Substances 0.000 claims description 51
- 229910052725 zinc Inorganic materials 0.000 claims description 51
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 50
- 229910052709 silver Inorganic materials 0.000 claims description 50
- 239000004332 silver Substances 0.000 claims description 50
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 48
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 46
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 43
- 229960005010 orotic acid Drugs 0.000 claims description 37
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 35
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 15
- HYBRYAPKQCZIAE-UHFFFAOYSA-N allocryptopine Chemical compound C1=C2CCN(C)CC3=C(OC)C(OC)=CC=C3CC(=O)C2=CC2=C1OCO2 HYBRYAPKQCZIAE-UHFFFAOYSA-N 0.000 claims description 15
- 230000029812 viral genome replication Effects 0.000 claims description 14
- AGSOWAZSCZVVDU-UHFFFAOYSA-N Allocryptopin Natural products C1=C2C(=O)CC=3C=C(OC)C(OC)=CC=3CN(C)CCC2=CC2=C1OCO2 AGSOWAZSCZVVDU-UHFFFAOYSA-N 0.000 claims description 13
- 208000031886 HIV Infections Diseases 0.000 claims description 11
- 239000007911 effervescent powder Substances 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 9
- 239000000829 suppository Substances 0.000 claims description 9
- 235000012431 wafers Nutrition 0.000 claims description 9
- 238000010253 intravenous injection Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 7
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 claims description 4
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000037357 HIV infectious disease Diseases 0.000 claims description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 4
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 claims description 4
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 claims description 4
- 239000000084 colloidal system Substances 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 abstract description 15
- 208000030507 AIDS Diseases 0.000 abstract description 14
- 230000010076 replication Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 2
- 241000388430 Tara Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- NGFLTEGALWMQIJ-UHFFFAOYSA-N allocryptopine Natural products COc1ccc2CC(=O)c3cc4OCOc4cc3CN(C)CCc2c1OC NGFLTEGALWMQIJ-UHFFFAOYSA-N 0.000 description 2
- HUIJAZQRYSCNED-UHFFFAOYSA-N alpha-allo-cryptopine Natural products C1CN(C)CC2=C(OC)C(OC)=CC=C2CC(=O)C2=CC(OC)=C(OC)C=C21 HUIJAZQRYSCNED-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241001017738 Chelidonium <beetle> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- -1 iron ions Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 HIV-1 및 HIV-2 바이러스 감염의 모든 단계 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제를 막기 위한 HIV 치료용 약제학적 혼합물 및 그 제조방법에 관한 것이다.The present invention relates to pharmaceutical mixtures for the treatment of HIV for preventing the replication of HIV-1 and HIV-2 viruses in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS, and methods for preparing the same. .
Description
본 발명은 HIV-1 및 HIV-2 바이러스 감염의 모든 단계 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및/또는 HIV-2 바이러스 복제를 막기 위한 약제학적 혼합물 및 HIV-1 및 HIV-2 바이러스 감염의 모든 단계 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제를 막기 위한 약제학적 혼합물의 제조방법에 관한 것이다.The present invention provides a pharmaceutical mixture for preventing HIV-1 and / or HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS and HIV-1 and HIV-2. A method for preparing a pharmaceutical mixture for preventing HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system at all stages of viral infection and in AIDS.
본원에서 사용된 용어“HIV 치료”및“그러한 치료가 필요한 환자에서 HIV의 치료”는 HIV-1 및/또는 HIV-2 환자를 치료하는 것을 의미한다. 또한,“HIV 복제를 막는”용어는 HIV-1 및/또는 HIV-2 바이러스 복제를 막는 것을 의미한다. 또한, 용어“HIV 바이러스”는 HIV-1 및/또는 HIV-2 바이러스를 의미한다. 용어“HIV 감염”은 HIV-1 및/또는 HIV-2 감염을 의미한다.As used herein, the terms “treatment of HIV” and “treatment of HIV in patients in need of such treatment” refer to the treatment of HIV-1 and / or HIV-2 patients. The term "blocking HIV replication" also means blocking HIV-1 and / or HIV-2 virus replication. The term “HIV virus” also refers to HIV-1 and / or HIV-2 virus. The term “HIV infection” means HIV-1 and / or HIV-2 infection.
본 발명은 HIV-1 및 HIV-2 바이러스 감염의 모든 단계 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및/또는 HIV-2 바이러스 복제를 막기 위한 약제학적 혼합물 및 HIV-1 및 HIV-2 바이러스 감염의 모든 단계 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제를 막기 위한 약제학적 혼합물의 제조방법에 관한 것이다.The present invention provides a pharmaceutical mixture for preventing HIV-1 and / or HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS and HIV-1 and HIV-2. A method for preparing a pharmaceutical mixture for preventing HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system at all stages of viral infection and in AIDS.
상기 혼합물은 후천성 면역 결핍증, 즉 AIDS의 치료에 사용된다.The mixture is used for the treatment of AIDS, ie AIDS.
발명의 개요Summary of the Invention
본 발명은 HIV-1 및 HIV-2 바이러스 감염 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제를 막기 위한 약제학적 혼합물에 관한 것으로 활성물질뿐만 아니라 이전에 공지된 담체 및/또는 보조 물질을 포함하며, 이들 중에서 10개 이상의 화학물질이 활성물질로서 존재하는 것을 특징으로 한다; 알로크립토핀이 1.0mg 내지 10.0mg의 양으로 존재하며; 니모디핀이 20.0mg 내지 100.0mg의 양으로 존재하며; 요오드화 칼륨이 120.0mg 내지 560.0mg의 양으로 존재하며; 요오드산 칼륨이 30.0mg 내지 140.0mg의 양으로 존재하며; 이눌린이 125.0mg 내지 375.0mg의 양으로 존재하며; 은이 0.10mg 내지 0.50mg의 양으로 존재하며; 아연이 10.0mg 내지 20.0mg의 양으로 존재하며; 크롬이 0.05mg 내지 0.20mg의 양으로 존재하며; 오로트산이 150.0mg 내지 500.0mg의 양으로 존재하며; 데스페린이 100.0mg 내지 300.0mg의 양으로 존재한다.The present invention relates to pharmaceutical mixtures for the prevention of HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system in HIV-1 and HIV-2 virus infections and AIDS. And / or auxiliary substances, wherein at least 10 of them are present as active substances; Allocryptopin is present in an amount from 1.0 mg to 10.0 mg; Nimodipine is present in an amount of 20.0 mg to 100.0 mg; Potassium iodide is present in an amount of 120.0 mg to 560.0 mg; Potassium iodide is present in an amount of 30.0 mg to 140.0 mg; Inulin is present in an amount of 125.0 mg to 375.0 mg; Silver is present in an amount of 0.10 mg to 0.50 mg; Zinc is present in an amount of 10.0 mg to 20.0 mg; Chromium is present in an amount from 0.05 mg to 0.20 mg; Orotic acid is present in an amount from 150.0 mg to 500.0 mg; Desferin is present in an amount of 100.0 mg to 300.0 mg.
요약summary
본 발명은 HIV-1 및 HIV-2 바이러스 감염의 모든 단계 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제를 막기 위한 약제학적 혼합물 및 치료적 조성물의 제조방법에 관한 것으로, 상기 치료적 조성물은 약제학적으로 유효량의 알로크립토핀, 니모디핀, 요오드화 칼륨, 요오드산 칼륨, 이눌린, 은, 아연, 크롬, 오로트산 및 데스페린으로 구성된다. 본 발명의 한 구체예로서, 상기 약제학적 혼합물 및 방법은 약제학적으로 유효량의 타라사스테롤 및 B-시토스테롤을 또한 포함한다.The present invention relates to a method for preparing pharmaceutical mixtures and therapeutic compositions for preventing HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS. The therapeutic composition consists of a pharmaceutically effective amount of allocriptopin, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid and desferin. In one embodiment of the invention, the pharmaceutical mixtures and methods also include pharmaceutically effective amounts of tarasosterol and B-sitosterol.
발명의 상세한 설명Detailed description of the invention
본 발명은 또한 HIV-1 및 HIV-2 바이러스 감염의 모든 단계 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제를 막기 위한 약제학적 혼합물의 제조방법에 관한 것으로, 1.0mg 내지 10.0mg 양의 알로크립토핀; 20.0mg 내지 100.0mg 양의 니모디핀; 120.0mg 내지 560.0mg 양의 요오드화 칼륨; 30.0mg 내지 140.0mg 양의 요오드산 칼륨; 125.0mg 내지 375.0mg 양의 이눌린; 0.10mg 내지 0.50mg 양의 은; 10.0mg 내지 20.0mg 양의 아연; 0.05mg 내지 0.20mg 양의 크롬; 150.0mg 내지 500.0mg 양의 오로트산; 100.0mg 내지 300.0mg 양의 데스페린을 대략 균일한 혼합물질이 형성될 때까지 실온에서 혼합한 다음, 압축하여 정제 또는 피막된 정제 형태 또는 웨이퍼, 좌제, 발포성 분말, 겔 또는 콜로이드 용액 또는 현탁액, 시럽, 체액에서 용해가능한 염 또는 근육내 또는 정맥내 주사용 액체 또는 앰플로 제조되는 것을 특징으로 한다.The present invention also relates to a method for preparing a pharmaceutical mixture for preventing replication of HIV-1 and HIV-2 viruses in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS. Allocriptopin in an amount of from 1 to 10.0 mg; Nimodipine in an amount of 20.0 mg to 100.0 mg; Potassium iodide in an amount of 120.0 mg to 560.0 mg; Potassium iodide in an amount of from 30.0 mg to 140.0 mg; Inulin in an amount of 125.0 mg to 375.0 mg; Silver in an amount of 0.10 mg to 0.50 mg; Zinc in an amount of 10.0 mg to 20.0 mg; Chromium in an amount of 0.05 mg to 0.20 mg; Orotic acid in an amount of 150.0 mg to 500.0 mg; Desperin in an amount of 100.0 mg to 300.0 mg is mixed at room temperature until an approximately homogeneous mixture is formed and then compressed to form a tablet or coated tablet or wafer, suppository, effervescent powder, gel or colloidal solution or suspension, syrup And soluble salts in body fluids or liquids or ampoules for intramuscular or intravenous injection.
HIV 감염 또는 후천성 면역 결핍증(AIDS) 환자의 치료와 관련된 기존의 출원에 있어서, 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제를 막기 위한 임의의 의약/약제학적 제제가 개시된 것은 없었다.In existing applications relating to the treatment of HIV infection or AIDS patients, no medicament / pharmaceutical preparations have been disclosed to prevent HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system. .
본 발명이 설명하고자 하는 것은 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제는 HIV-1 및 HIV-2 바이러스와 사람 면역계의 CD4 세포사이의 엑세이토노-엑시머 상호작용이라는 것을 토대로 한다.The present invention is intended to explain that HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system is an exeitono-excimer interaction between HIV-1 and HIV-2 viruses and CD4 cells of the human immune system. do.
HIV-1 및 HIV-2 바이러스 감염 및 AIDS의 치료를 목적으로 하는 치료의 개시는 환자의 몸에 HIV-1 및 HIV-2 복제를 유발하는 작용기전을 완전히 막는 전달물질이 감소된다.Initiation of treatment aimed at the treatment of HIV-1 and HIV-2 viral infections and AIDS results in a decrease in the transporter that completely blocks the mechanisms of action that cause HIV-1 and HIV-2 replication in the patient's body.
하기 물질은 이러한 것을 도와주는 것으로 입증되었다: 알로크립토핀, 체리도늄 메이우스(Chelidonium maius) 식물에서 발견된 알칼로이드, 니모디핀, 요오드화 칼륨, 요오드산 칼륨, 이눌린, 은, 아연, 크롬, 오로트산 및 데스페린. 타라사스테롤 및 B-시토스테롤도 이에 속한다.The following substances have been demonstrated to help: Alkaloids, Nimodipine, Potassium Iodide, Potassium Iodide, Inulin, Silver, Zinc, Chromium, Orlot Found in AlloCryptopin, Chelidonium maius Plants Acid and desferrin. Tarasosterol and B-sitosterol are also included in this.
알로크립토핀은 뉴클레오티드 포스포디에스테라아제 차단제이며, 니모디핀은 칼슘 채널 차단제이며, 요오드화 칼륨은 산성 환경에서 요오드산 칼륨과 혼합될 때 요오드 유리 라디칼을 생성하며, 이눌린은 체내에서 분해되지 않는 다당류이며, 은, 아연 및 크롬은 효소 작용에서 역할을 하는 요소이며, 데스페린은 철 이온을 킬레이트 화합물로 만들며, 오로트산은 뉴클레오티드 화합물의 선구물질임이 공지되어 있다.Allocrippine is a nucleotide phosphodiesterase blocker, nimodipine is a calcium channel blocker, potassium iodide produces iodine free radicals when mixed with potassium iodide in an acidic environment, inulin is a polysaccharide that does not degrade in the body, It is known that, zinc and chromium are elements that play a role in enzyme action, desferin makes iron ions into chelate compounds, and orotic acid is a precursor to nucleotide compounds.
그러나, 상술한 물질들은 함께 사용된 적이 없으며 특히, 이들은 본원에서 개시한 바와 같은 치료적 적용에 함께 사용되지 않았다.However, the materials mentioned above have never been used together and in particular they have not been used together in therapeutic applications as disclosed herein.
본 발명의 목적은 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제를 막는 약제학적 혼합물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical mixture which prevents the replication of HIV-1 and HIV-2 viruses in CD4 + cells of the human immune system.
본 발명은 HIV-1 및 HIV-2 바이러스 감염의 모든 단계 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및 HIV-2 바이러스 복제를 막기 위한 약제학적 혼합물을 제공하며, 활성물질뿐만 아니라 이전에 공지된 담체 및/또는 보조 물질을 포함하며, 이들 중에서 10개 이상의 화학물질이 활성물질로서 존재하는 것을 특징으로 한다:The present invention provides pharmaceutical mixtures for the prevention of HIV-1 and HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS, It includes known carriers and / or auxiliary substances, characterized in that at least ten chemical substances are present as active substances:
- 알로크립토핀이 1.0mg 내지 10.0mg의 양으로 존재하며,Allocyprupine is present in an amount from 1.0 mg to 10.0 mg,
- 니모디핀이 20.0mg 내지 100.0mg의 양으로 존재하며, Nimodipine is present in an amount from 20.0 mg to 100.0 mg,
- 요오드화 칼륨이 120.0mg 내지 560.0mg의 양으로 존재하며,Potassium iodide is present in an amount from 120.0 mg to 560.0 mg,
- 요오드산 칼륨이 30.0mg 내지 140.0mg의 양으로 존재하며, Potassium iodide is present in an amount from 30.0 mg to 140.0 mg,
- 이눌린이 125.0mg 내지 375.0mg의 양으로 존재하며, Inulin is present in an amount from 125.0 mg to 375.0 mg,
- 은이 0.10mg 내지 0.50mg의 양으로 존재하며,Silver is present in an amount from 0.10 mg to 0.50 mg,
- 아연이 10.0mg 내지 20.0mg의 양으로 존재하며, Zinc is present in an amount from 10.0 mg to 20.0 mg,
- 크롬이 0.05mg 내지 0.20mg의 양으로 존재하며,Chromium is present in an amount from 0.05 mg to 0.20 mg,
- 오로트산이 150.0mg 내지 500.0mg의 양으로 존재하며, Orotic acid is present in an amount from 150.0 mg to 500.0 mg,
- 데스페린이 100.0mg 내지 300.0mg의 양으로 존재한다.Desferin is present in an amount from 100.0 mg to 300.0 mg.
- 알로크립토핀 함량이 10.0mg이며,-Allokryptopin content is 10.0mg,
- 니모디핀 함량이 100.0mg이며, Nimodipine content is 100.0mg,
- 요오드화 칼륨 함량이 560.0mg이며,-Potassium iodide content is 560.0 mg,
- 요오드산 칼륨 함량이 140.0mg이며, -Potassium iodide content is 140.0 mg,
- 이눌린 함량이 375.0mg이며, -Inulin content is 375.0 mg,
- 은 함량이 0.50mg이며,-Has a silver content of 0.50 mg,
- 아연 함량이 20.0mg이며, -Zinc content is 20.0 mg,
- 크롬 함량이 0.20mg이며,Chromium content is 0.20 mg,
- 오로트산 함량이 500.0mg이며, -Orotic acid content is 500.0 mg,
- 데스페린 함량이 300.0mg일때 유익하다.Useful when desperin content is 300.0mg.
- 알로크립토핀 함량이 4.50mg이며,-Allocryptofine content is 4.50mg,
- 니모디핀 함량이 60.0mg이며, Nimodipine content is 60.0mg,
- 요오드화 칼륨 함량이 340.0mg이며,-Potassium iodide content is 340.0 mg,
- 요오드산 칼륨 함량이 85.0mg이며, -Potassium iodide content is 85.0 mg,
- 이눌린 함량이 250.0mg이며, -Inulin content is 250.0 mg,
- 은 함량이 0.30mg이며,-Has a silver content of 0.30 mg,
- 아연 함량이 15.0mg이며, -Zinc content is 15.0 mg,
- 크롬 함량이 0.125mg이며,Chromium content is 0.125 mg,
- 오로트산 함량이 325.0mg이며, -Ortho acid content is 325.0 mg,
- 데스페린 함량이 200.0mg일때 유익하다.It is beneficial when the desferin content is 200.0mg.
- 알로크립토핀 함량이 4.50mg이며,-Allocryptofine content is 4.50mg,
- 니모디핀 함량이 60.0mg이며, Nimodipine content is 60.0mg,
- 요오드화 칼륨 함량이 340.0mg이며,-Potassium iodide content is 340.0 mg,
- 요오드산 칼륨 함량이 85.0mg이며, -Potassium iodide content is 85.0 mg,
- 이눌린 함량이 250.0mg이며, -Inulin content is 250.0 mg,
- 은 함량이 0.30mg이며,-Has a silver content of 0.30 mg,
- 아연 함량이 15.0mg이며, -Zinc content is 15.0 mg,
- 크롬 함량이 0.125mg이며,Chromium content is 0.125 mg,
- 오로트산 함량이 325.0mg이며, -Ortho acid content is 325.0 mg,
- 데스페린 함량이 200.0mg이며,Desperin content is 200.0 mg,
- 타라사스테롤 함량이 350mg이며,-Tarasosterol content is 350mg,
- B-시토스테롤 함량이 400mg일때 유익하다.It is beneficial when the B-sitosterol content is 400 mg.
- 알로크립토핀 함량이 1.0mg이며,-Allokryptopin content is 1.0mg,
- 니모디핀 함량이 20.0mg이며, -Nimodipine content is 20.0 mg,
- 요오드화 칼륨 함량이 120.0mg이며,-Potassium iodide content is 120.0 mg,
- 요오드산 칼륨 함량이 30.0mg이며, -Potassium iodide content is 30.0 mg,
- 이눌린 함량이 125.0mg이며, -Inulin content is 125.0 mg,
- 은 함량이 0.10mg이며,-Has a silver content of 0.10 mg,
- 아연 함량이 10.0mg이며, Zinc content is 10.0 mg,
- 크롬 함량이 0.05mg이며,Chromium content is 0.05 mg,
- 오로트산 함량이 250.0mg이며, -Ortho acid content is 250.0 mg,
- 데스페린 함량이 100.0mg이며,-The desperin content is 100.0 mg,
- 타라사스테롤 함량이 250mg이며,-The tarasasterol content is 250mg,
- B-시토스테롤 함량이 300mg일때 유익하다.It is beneficial when the B-sitosterol content is 300 mg.
- 알로크립토핀 함량이 1.0mg이며,-Allokryptopin content is 1.0mg,
- 니모디핀 함량이 20.0mg이며, -Nimodipine content is 20.0 mg,
- 요오드화 칼륨 함량이 120.0mg이며,-Potassium iodide content is 120.0 mg,
- 요오드산 칼륨 함량이 30.0mg이며, -Potassium iodide content is 30.0 mg,
- 이눌린 함량이 125.0mg이며, -Inulin content is 125.0 mg,
- 은 함량이 0.10mg이며,-Has a silver content of 0.10 mg,
- 아연 함량이 10.0mg이며, Zinc content is 10.0 mg,
- 크롬 함량이 0.05mg이며,Chromium content is 0.05 mg,
- 오로트산 함량이 250.0mg이며, -Ortho acid content is 250.0 mg,
- 데스페린 함량이 100.0mg일때 유익하다.It is beneficial when the desperin content is 100.0 mg.
알로크립토핀 대 니모디핀 대 요오드화 칼륨 대 요오드산 칼륨 대 이눌린 대 은 대 아연 대 크롬 대 오로트산 대 데스페린의 중량비가 일반적으로 1:20:120:30:125:0.1:10:0.05:250:100으로 유지될 때 유익하다.The weight ratio of allocryptopin to nimodipine to potassium iodide to potassium iodide to inulin versus silver to zinc to chromium to orotic acid to desferin is generally 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250 Useful when maintained at: 100.
상기 성분의 혼합물이 정제 또는 피막된 정제 또는 웨이퍼 또는 좌제 또는 발포성 분말 또는 겔 또는 콜로이드 용액의 형태일 때 유익하다.It is advantageous when the mixture of these ingredients is in the form of tablets or coated tablets or wafers or suppositories or effervescent powders or gels or colloidal solutions.
상기 성분의 혼합물이 현탁액 또는 시럽 또는 체액에서 용해가능한 염 또는 근육내 또는 정맥내 주사용 액체의 형태일 때 유익하다.It is advantageous when the mixture of these ingredients is in the form of a suspension or syrup or a salt soluble in bodily fluids or a liquid for intramuscular or intravenous injection.
HIV-1 및 HIV-2 바이러스 감염의 모든 단계 및 AIDS에서 사람 면역계의 CD4+ 세포중의 HIV-1 및/또는 HIV-2 바이러스 복제를 막기 위한 약제학적 혼합물의 제조는 하기 성분을 균질 혼합물이 형성될 때까지 실온에서 혼합하는 것을 특징으로 한다:Preparation of pharmaceutical mixtures to prevent HIV-1 and / or HIV-2 virus replication in CD4 + cells of the human immune system at all stages of HIV-1 and HIV-2 virus infection and in AIDS results in a homogeneous mixture of the following components: Mix at room temperature until:
- 1.0mg 내지 10.0mg 양의 알로크립토핀,Allocriptopin in an amount from 1.0 mg to 10.0 mg,
- 20.0mg 내지 100.0mg 양의 니모디핀, Nimodipine in an amount of 20.0 mg to 100.0 mg,
- 120.0mg 내지 560.0mg 양의 요오드화 칼륨,Potassium iodide in an amount of 120.0 mg to 560.0 mg,
- 30.0mg 내지 140.0mg 양의 요오드산 칼륨, Potassium iodide in an amount of from 30.0 mg to 140.0 mg,
- 125.0mg 내지 375.0mg 양의 이눌린, Inulin in an amount of 125.0 mg to 375.0 mg,
- 0.10mg 내지 0.50mg 양의 은,Silver in an amount of 0.10 mg to 0.50 mg,
- 10.0mg 내지 20.0mg 양의 아연, Zinc in an amount of 10.0 mg to 20.0 mg,
- 0.05mg 내지 0.20mg 양의 크롬,Chromium in an amount of from 0.05 mg to 0.20 mg,
- 150.0mg 내지 500.0mg 양의 오로트산, Orotic acid in an amount from 150.0 mg to 500.0 mg,
- 100.0mg 내지 300.0mg 양의 데스페린.Desferin in an amount of 100.0 mg to 300.0 mg.
- 알로크립토핀 함량이 10.0mg이며,-Allokryptopin content is 10.0mg,
- 니모디핀 함량이 100.0mg이며, Nimodipine content is 100.0mg,
- 요오드화 칼륨 함량이 560.0mg이며,-Potassium iodide content is 560.0 mg,
- 요오드산 칼륨 함량이 140.0mg이며, -Potassium iodide content is 140.0 mg,
- 이눌린 함량이 375.0mg이며, -Inulin content is 375.0 mg,
- 은 함량이 0.50mg이며,-Has a silver content of 0.50 mg,
- 아연 함량이 20.0mg이며, -Zinc content is 20.0 mg,
- 크롬 함량이 0.20mg이며,Chromium content is 0.20 mg,
- 오로트산 함량이 500.0mg이며, -Orotic acid content is 500.0 mg,
- 데스페린 함량이 300.0mg일때 유익하다.Useful when desperin content is 300.0mg.
- 알로크립토핀 함량이 4.50mg이며,-Allocryptofine content is 4.50mg,
- 니모디핀 함량이 60.0mg이며, Nimodipine content is 60.0mg,
- 요오드화 칼륨 함량이 340.0mg이며,-Potassium iodide content is 340.0 mg,
- 요오드산 칼륨 함량이 85.0mg이며, -Potassium iodide content is 85.0 mg,
- 이눌린 함량이 250.0mg이며, -Inulin content is 250.0 mg,
- 은 함량이 0.30mg이며,-Has a silver content of 0.30 mg,
- 아연 함량이 15.0mg이며, -Zinc content is 15.0 mg,
- 크롬 함량이 0.125mg이며,Chromium content is 0.125 mg,
- 오로트산 함량이 325.0mg이며, -Ortho acid content is 325.0 mg,
- 데스페린 함량이 200.0mg일때 유익하다.It is beneficial when the desferin content is 200.0mg.
- 알로크립토핀 함량이 1.0mg이며,-Allokryptopin content is 1.0mg,
- 니모디핀 함량이 20.0mg이며, -Nimodipine content is 20.0 mg,
- 요오드화 칼륨 함량이 120.0mg이며,-Potassium iodide content is 120.0 mg,
- 요오드산 칼륨 함량이 30.0mg이며, -Potassium iodide content is 30.0 mg,
- 이눌린 함량이 125.0mg이며, -Inulin content is 125.0 mg,
- 은 함량이 0.10mg이며,-Has a silver content of 0.10 mg,
- 아연 함량이 10.0mg이며, Zinc content is 10.0 mg,
- 크롬 함량이 0.05mg이며,Chromium content is 0.05 mg,
- 오로트산 함량이 250.0mg이며, -Ortho acid content is 250.0 mg,
- 데스페린 함량이 100.0mg일때 유익하다.It is beneficial when the desperin content is 100.0 mg.
알로크립토핀 대 니모디핀 대 요오드화 칼륨 대 요오드산 칼륨 대 이눌린 대 은 대 아연 대 크롬 대 오로트산 대 데스페린의 중량비가 일반적으로 1:20:120:30:125:0.1:10:0.05:250:100으로 유지될 때 유익하다.The weight ratio of allocryptopin to nimodipine to potassium iodide to potassium iodide to inulin versus silver to zinc to chromium to orotic acid to desferin is generally 1: 20: 120: 30: 125: 0.1: 10: 0.05: 250 Useful when maintained at: 100.
약제학적 혼합물 및 이를 제조하기 위한 방법은 약제학적으로 유효량의 타라사스테롤 및 B-시토스테롤을 또한 포함한다. 상기 약제학적 혼합물 및 이를 제조하기 위한 방법은 1.0mg 내지 10.0mg 양의 알로크립토핀, 20.0mg 내지 100.0mg 양의 니모디핀, 120.0mg 내지 560.0mg 양의 요오드화 칼륨, 30.0mg 내지 140.0mg 양의 요오드산 칼륨, 125.0mg 내지 375.0mg 양의 이눌린, 0.10mg 내지 0.50mg 양의 은, 10.0mg 내지 20.0mg 양의 아연, 0.05mg 내지 0.20mg 양의 크롬, 150.0mg 내지 500.0mg 양의 오로트산, 100.0mg 내지 300.0mg 양의 데스페린, 250mg 내지 400mg 양의 타라사스테롤 및 300mg 내지 500mg 양의 B-시토스테롤을 균일한 혼합물질이 형성될 때까지 실온에서 혼합한 다음, 압축하여 정제 또는 피막된 정제 형태 또는 웨이퍼, 좌제, 발포성 분말, 겔 또는 콜로이드 용액 또는 현탁액, 시럽, 체액에서 용해가능한 염 또는 근육내 또는 정맥내 주사용 액체 또는 앰플로 제조되는 것을 특징으로 할 때 유익하다.Pharmaceutical mixtures and methods for preparing the same also include pharmaceutically effective amounts of tarasosterol and B-sitosterol. The pharmaceutical mixture and the method for preparing the same are allocryptopine in an amount of 1.0 mg to 10.0 mg, nimodipine in an amount of 20.0 mg to 100.0 mg, potassium iodide in an amount of 120.0 mg to 560.0 mg, and iodine in an amount of 30.0 mg to 140.0 mg Potassium acid, inulin in an amount of 125.0 mg to 375.0 mg, silver in an amount of 0.10 mg to 0.50 mg, zinc in an amount of 10.0 mg to 20.0 mg, chromium in an amount of 0.05 mg to 0.20 mg, orotic acid in an amount of 150.0 mg to 500.0 mg, Desferin in an amount of 100.0 mg to 300.0 mg, taraxasterol in an amount of 250 mg to 400 mg and B-sitosterol in an amount of 300 mg to 500 mg are mixed at room temperature until a homogeneous mixture is formed, and then compressed or purified tablets It is advantageous when produced in the form or as a wafer, suppository, effervescent powder, gel or colloidal solution or suspension, syrup, salt soluble in bodily fluids or liquid or ampoule for intramuscular or intravenous injection.
알로크립토핀 대 니모디핀 대 요오드화 칼륨 대 요오드산 칼륨 대 이눌린 대 은 대 아연 대 크롬 대 오로트산 대 데스페린 대 타라사스테롤 대 B-시토스테롤의 중량비가 일반적으로 1:20:120:30:125:0.1:10:0.05:250:100:400:500으로 유지될 때 유익하다.The weight ratio of allocryptopin to nimodipine to potassium iodide to potassium iodide to potassium inulin to silver to zinc to chromium to orotic acid to desferrin to tarasasterol to B-sitosterol is generally 1: 20: 120: 30: 125 Useful when maintained at: 0.1: 10: 0.05: 250: 100: 400: 500.
알로크립토핀 대 니모디핀 대 요오드화 칼륨 대 요오드산 칼륨 대 이눌린 대 은 대 아연 대 크롬 대 오로트산 대 데스페린 대 타라사스테롤 대 B-시토스테롤의 중량비가 일반적으로 1:20:120:30:125:0.1:10:0.05:250:100:350:400으로 유지될 때 또한 유익하다.The weight ratio of allocryptopin to nimodipine to potassium iodide to potassium iodide to potassium inulin to silver to zinc to chromium to orotic acid to desferrin to tarasasterol to B-sitosterol is generally 1: 20: 120: 30: 125 It is also beneficial when maintained at: 0.1: 10: 0.05: 250: 100: 350: 400.
상기 성분의 혼합물이 정제 또는 피막된 정제 또는 웨이퍼 또는 좌제 또는 발포성 분말 또는 겔 또는 콜로이드 용액의 형태일 때 유익하다.It is advantageous when the mixture of these ingredients is in the form of tablets or coated tablets or wafers or suppositories or effervescent powders or gels or colloidal solutions.
상기 성분의 혼합물이 현탁액 또는 시럽 또는 체액에서 용해가능한 염 또는 근육내 또는 정맥내 주사용 액체의 형태일 때 유익하다.It is advantageous when the mixture of these ingredients is in the form of a suspension or syrup or a salt soluble in bodily fluids or a liquid for intramuscular or intravenous injection.
본 발명의 약제학적 혼합물의 이로운 효과는 HIV-1 및 HIV-2 바이러스 복제와 관련된 세포내 작용을 막을뿐 아니라 HIV 바이러스 캡슐의 gp 160 단백질을 사람 면역계의 CD4+ 세포의 수용체에 부착하는 작용기전을 막는 것이다.The beneficial effects of the pharmaceutical mixtures of the present invention not only prevent the intracellular actions associated with HIV-1 and HIV-2 virus replication but also the mechanism of action of attaching the gp 160 protein of the HIV virus capsule to the receptors of CD4 + cells of the human immune system. will be.
실시예Example 1 One
약제학적 혼합물의 함량:Content of Pharmaceutical Mixtures:
- 알로크립토핀 양이 10.0mg이며,-The amount of allocrippinin is 10.0 mg,
- 니모디핀 양이 100.0mg이며, Nimodipine amount is 100.0mg,
- 요오드화 칼륨 양이 560.0mg이며,The amount of potassium iodide is 560.0 mg,
- 요오드산 칼륨 양이 140.0mg이며, The amount of potassium iodide is 140.0 mg,
- 이눌린 양이 375.0mg이며, The amount of inulin is 375.0 mg,
- 은 양이 0.50mg이며,-The amount of silver is 0.50 mg,
- 아연 양이 20.0mg이며, -The amount of zinc is 20.0 mg,
- 크롬 양이 0.20mg이며,-The amount of chromium is 0.20 mg,
- 오로트산 양이 500.0mg이며, -The amount of oroic acid is 500.0 mg,
- 데스페린 양이 300.0mg임Desperin amount is 300.0 mg
약제학적 혼합물의 제조:Preparation of Pharmaceutical Mixtures:
알로크립토핀 10.0mg, 니모디핀 100.0mg, 요오드화 칼륨 560.0mg, 요오드산 칼륨 140.0mg, 이눌린 375.0mg, 은 0.50mg, 아연 20.0mg, 크롬 0.20mg, 오로트산 500.0mg, 데스페린 300.0mg을 실온에서 혼합하였다.AlloCryptopin 10.0mg, Nimodipine 100.0mg, Potassium Iodide 560.0mg, Potassium Iodide 140.0mg, Inulin 375.0mg, Silver 0.50mg, Zinc 20.0mg, Chromium 0.20mg, Orotic Acid 500.0mg, Desperin 300.0mg Mixed in.
모든 성분을 부가한 후, 균일한 물질이 형성될 때까지 약 10-20분 동안 이들을 함께 혼합하였다. 이어, 상기 혼합물을 압축하여 정제, 피막된 정제 또는 웨이퍼, 좌제, 발포성 분말, 겔 또는 콜로이드 용액으로 제조하였다.After all the ingredients were added, they were mixed together for about 10-20 minutes until a uniform material formed. The mixture was then compressed to prepare tablets, coated tablets or wafers, suppositories, effervescent powders, gels or colloidal solutions.
실시예Example 2 2
약제학적 혼합물의 함량:Content of Pharmaceutical Mixtures:
- 알로크립토핀 양이 1.0mg이며,-The amount of allocrippinin is 1.0mg,
- 니모디핀 양이 20.0mg이며, Nimodipine amount is 20.0mg,
- 요오드화 칼륨 양이 120.0mg이며,The amount of potassium iodide is 120.0 mg,
- 요오드산 칼륨 양이 30.0mg이며, -The amount of potassium iodide is 30.0 mg,
- 이눌린 양이 125.0mg이며, The amount of inulin is 125.0 mg,
- 은 양이 0.10mg이며,-The amount of silver is 0.10 mg,
- 아연 양이 10.0mg이며, -The amount of zinc is 10.0 mg,
- 크롬 양이 0.05mg이며,The amount of chromium is 0.05 mg,
- 오로트산 양이 150.0mg이며, The amount of oroic acid is 150.0 mg,
- 데스페린 양이 100.0mg임.Desperin amount is 100.0 mg.
약제학적 혼합물의 제조:Preparation of Pharmaceutical Mixtures:
알로크립토핀 1.0mg, 니모디핀 20.0mg, 요오드화 칼륨 120.0mg, 요오드산 칼륨 30.0mg, 이눌린 125.0mg, 은 0.10mg, 아연 10.0mg, 크롬 0.05mg, 오로트산 150.0mg, 데스페린 100.0mg을 실온에서 혼합하였다.AlloCryptopin 1.0mg, Nimodipine 20.0mg, Potassium Iodide 120.0mg, Potassium Iodide 30.0mg, Inulin 125.0mg, Silver 0.10mg, Zinc 10.0mg, Chromium 0.05mg, Orotic Acid 150.0mg, Desperin 100.0mg Mixed in.
모든 성분을 부가한 후, 균일한 물질이 형성될 때까지 약 10-20분 동안 이들을 함께 혼합하였다. After all the ingredients were added, they were mixed together for about 10-20 minutes until a uniform material formed.
이어, 상기 혼합물을 현탁액, 시럽, 체액에서 용해가능한 염 또는 근육내 또는 정맥내 주사용 액체 또는 앰플로 제조하였다.The mixture was then prepared as suspensions, syrups, salts soluble in body fluids or liquids or ampoules for intramuscular or intravenous injection.
실시예Example 3 3
약제학적 혼합물의 함량:Content of Pharmaceutical Mixtures:
- 알로크립토핀 양이 10.0mg이며,-The amount of allocrippinin is 10.0 mg,
- 니모디핀 양이 100.0mg이며, Nimodipine amount is 100.0mg,
- 요오드화 칼륨 양이 560.0mg이며,The amount of potassium iodide is 560.0 mg,
- 요오드산 칼륨 양이 140.0mg이며, The amount of potassium iodide is 140.0 mg,
- 이눌린 양이 375.0mg이며, The amount of inulin is 375.0 mg,
- 은 양이 0.50mg이며,-The amount of silver is 0.50 mg,
- 아연 양이 20.0mg이며, -The amount of zinc is 20.0 mg,
- 크롬 양이 0.20mg이며,-The amount of chromium is 0.20 mg,
- 오로트산 양이 500.0mg이며, -The amount of oroic acid is 500.0 mg,
- 데스페린 양이 300.0mg이며, -The amount of desperin is 300.0 mg,
- 타라사스테롤 양이 400mg이며, -The amount of tarasasterol is 400mg,
- B-시토스테롤 양이 500mg임.The amount of B-sitosterol is 500 mg.
약제학적 혼합물의 제조:Preparation of Pharmaceutical Mixtures:
알로크립토핀 10.0mg, 니모디핀 100.0mg, 요오드화 칼륨 560.0mg, 요오드산 칼륨 140.0mg, 이눌린 375.0mg, 은 0.50mg, 아연 20.0mg, 크롬 0.20mg, 오로트산 500.0mg, 데스페린 300.0mg, 타라사스테롤 400mg 및 B-시토스테롤 500mg을 실온에서 혼합하였다.AlloCryptopin 10.0mg, Nimodipine 100.0mg, Potassium Iodide 560.0mg, Potassium Iodide 140.0mg, Inulin 375.0mg, Silver 0.50mg, Zinc 20.0mg, Chromium 0.20mg, Orotic Acid 500.0mg, Desperin 300.0mg, Tara 400 mg of sasterol and 500 mg of B-sitosterol were mixed at room temperature.
모든 성분을 부가한 후, 균일한 물질이 형성될 때까지 약 10-20분 동안 이들을 함께 혼합하였다. 이어, 상기 혼합물을 압축하여 정제, 피막된 정제 또는 웨이퍼, 좌제, 발포성 분말, 겔 또는 콜로이드 용액으로 제조하였다.After all the ingredients were added, they were mixed together for about 10-20 minutes until a uniform material formed. The mixture was then compressed to prepare tablets, coated tablets or wafers, suppositories, effervescent powders, gels or colloidal solutions.
실시예Example 4 4
약제학적 혼합물의 함량:Content of Pharmaceutical Mixtures:
- 알로크립토핀 양이 1.0mg이며,-The amount of allocrippinin is 1.0mg,
- 니모디핀 양이 20.0mg이며, Nimodipine amount is 20.0mg,
- 요오드화 칼륨 양이 120.0mg이며,The amount of potassium iodide is 120.0 mg,
- 요오드산 칼륨 양이 30.0mg이며, -The amount of potassium iodide is 30.0 mg,
- 이눌린 양이 125.0mg이며, The amount of inulin is 125.0 mg,
- 은 양이 0.10mg이며,-The amount of silver is 0.10 mg,
- 아연 양이 10.0mg이며, -The amount of zinc is 10.0 mg,
- 크롬 양이 0.05mg이며,The amount of chromium is 0.05 mg,
- 오로트산 양이 150.0mg이며, The amount of oroic acid is 150.0 mg,
- 데스페린 양이 100.0mg이며,-The amount of desperin is 100.0 mg,
- 타라사스테롤 양이 250mg이며, -The amount of tarasasterol is 250mg,
- B-시토스테롤 양이 300mg임.The amount of B-sitosterol is 300 mg.
약제학적 혼합물의 제조:Preparation of Pharmaceutical Mixtures:
알로크립토핀 1.0mg, 니모디핀 20.0mg, 요오드화 칼륨 120.0mg, 요오드산 칼륨 30.0mg, 이눌린 125.0mg, 은 0.10mg, 아연 10.0mg, 크롬 0.05mg, 오로트산 150.0mg, 데스페린 100.0mg, 타라사스테롤 250mg 및 B-시토스테롤 300mg을 실온에서 혼합하였다.AlloCryptopin 1.0mg, Nimodipine 20.0mg, Potassium Iodide 120.0mg, Potassium Iodide 30.0mg, Inulin 125.0mg, Silver 0.10mg, Zinc 10.0mg, Chromium 0.05mg, Orotic Acid 150.0mg, Desperin 100.0mg, Tara 250 mg of sasterol and 300 mg of B-sitosterol were mixed at room temperature.
모든 성분을 부가한 후, 균일한 물질이 형성될 때까지 약 10-20분 동안 이들을 함께 혼합하였다. After all the ingredients were added, they were mixed together for about 10-20 minutes until a uniform material formed.
이어, 상기 혼합물을 현탁액, 시럽, 체액에서 용해가능한 염 또는 근육내 또는 정맥내 주사용 액체 또는 앰플로 제조하였다.The mixture was then prepared as suspensions, syrups, salts soluble in body fluids or liquids or ampoules for intramuscular or intravenous injection.
용어“약제학적으로 유효량”은 본 발명의 약제학적 혼합물(알로크립토핀, 니모디핀, 요오드화 칼륨, 요오드산 칼륨, 이눌린, 은, 아연, 크롬, 오로트산 및 데스페린의 혼합물을 포함하는)의 유효량을 의미함을 이해되어야 한다. 특정 환자에서 소망하는 치료적 반응을 달성하기 위해 본 발명의 약제학적 조성물의 실질적인 투여량, 성분 및 투여방법은 다양할 수 있다. 선택된 투여량은 특정 화합물의 활성, 투여경로, 치료할 상태의 심각성 및 상태 및 치료할 환자의 이전 병력에 따라 다를 것이다. 그러나, 소망하는 치료적 효과를 달성하고 이러한 소망하는 효과가 달성될 때까지 투여량을 점자 증가시키기 위해 필요로 하는 양보다 낮은 양에서 화합물의 투여를 시작하는 것은 당해 기술 범위내이다.The term "pharmaceutically effective amount" refers to a pharmaceutical mixture of the present invention (including a mixture of allocryptopine, nimodipine, potassium iodide, potassium iodide, inulin, silver, zinc, chromium, orotic acid and desferin). It should be understood that it refers to an effective amount. Substantial dosages, components, and methods of administration of the pharmaceutical compositions of the present invention may vary to achieve the desired therapeutic response in a particular patient. The dosage chosen will depend on the activity of the particular compound, the route of administration, the severity and condition of the condition to be treated and the previous history of the patient to be treated. However, it is within the skill in the art to begin administering the compound at an amount lower than necessary to achieve the desired therapeutic effect and to increase the dosage until the desired effect is achieved.
Claims (31)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/353,483 US20030203045A1 (en) | 2002-04-30 | 2003-01-29 | Therapeutic composition for the treatment of HIV-1 and HIV-2 |
| US10/353,483 | 2003-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050094461A true KR20050094461A (en) | 2005-09-27 |
Family
ID=32823743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057013692A Withdrawn KR20050094461A (en) | 2003-01-29 | 2004-01-29 | A therapeutic composition for the treatment of hiv-1 and hiv-2 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1589961A4 (en) |
| JP (1) | JP2006516633A (en) |
| KR (1) | KR20050094461A (en) |
| CN (1) | CN1747726A (en) |
| AU (1) | AU2004206996A1 (en) |
| CA (1) | CA2514252A1 (en) |
| RU (1) | RU2005123957A (en) |
| WO (1) | WO2004066954A2 (en) |
| ZA (1) | ZA200505977B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810625B (en) * | 2010-04-09 | 2012-05-23 | 上海新康制药厂 | Application of taraxasterol |
| JP2021161045A (en) * | 2020-03-31 | 2021-10-11 | 株式会社古川リサーチオフィス | Zinc compound mixed composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970212A (en) * | 1982-05-18 | 1990-11-13 | Nowicky Wassili | Method of treating human illnesses which compromise the ability to mount an effective immunological response |
| CA1337047C (en) * | 1988-08-18 | 1995-09-19 | Peter Dodd Cooper | Gamma inulin compositions |
| DE69027026T2 (en) * | 1989-03-31 | 1996-09-26 | Childrens Medical Center | TREATING AIDS, DEMENTIA, MYELOPATHY AND BLINDNESS |
| US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
| RU2107502C1 (en) * | 1997-03-27 | 1998-03-27 | Открытое акционерное общество "Ветеринарные препараты" | Iodine monochloride, veterinary preparation possessing wide range of action |
| AU4944500A (en) * | 1999-06-29 | 2001-01-31 | Robert H. Jacobs | A method for optimizing immune activity in the treatment of auto-immune diseases and chronic immune conditions |
| RU2195277C2 (en) * | 2001-02-09 | 2002-12-27 | Третьяков Василий Васильевич | Method of treatment of hiv-infection |
| GB2374008B (en) * | 2001-04-04 | 2005-03-16 | John Carter | Pharmaceutical compositions comprising copper and zinc |
| PL353693A1 (en) * | 2002-04-30 | 2003-11-03 | Bogusław Jeleń | Compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd4+ cells of human immunological system at all stages of infection and in the aids syndrome as well as method of manufacture of compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd+ cells of human immunological system at all stages of infection and in the aids syndrome |
-
2004
- 2004-01-29 AU AU2004206996A patent/AU2004206996A1/en not_active Abandoned
- 2004-01-29 EP EP04706521A patent/EP1589961A4/en not_active Withdrawn
- 2004-01-29 CN CNA2004800039434A patent/CN1747726A/en active Pending
- 2004-01-29 WO PCT/US2004/002536 patent/WO2004066954A2/en not_active Application Discontinuation
- 2004-01-29 CA CA002514252A patent/CA2514252A1/en not_active Abandoned
- 2004-01-29 JP JP2006503151A patent/JP2006516633A/en active Pending
- 2004-01-29 KR KR1020057013692A patent/KR20050094461A/en not_active Withdrawn
- 2004-01-29 RU RU2005123957/15A patent/RU2005123957A/en not_active Application Discontinuation
-
2005
- 2005-07-26 ZA ZA200505977A patent/ZA200505977B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006516633A (en) | 2006-07-06 |
| WO2004066954A2 (en) | 2004-08-12 |
| ZA200505977B (en) | 2006-05-31 |
| EP1589961A4 (en) | 2006-02-15 |
| WO2004066954A3 (en) | 2005-03-17 |
| CA2514252A1 (en) | 2004-08-12 |
| AU2004206996A1 (en) | 2004-08-12 |
| EP1589961A2 (en) | 2005-11-02 |
| CN1747726A (en) | 2006-03-15 |
| RU2005123957A (en) | 2006-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH04288019A (en) | Extract of gingko biloba leaves and use thereof | |
| CA2450359A1 (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| KR20050094461A (en) | A therapeutic composition for the treatment of hiv-1 and hiv-2 | |
| CA2434526A1 (en) | Methods of administering epothilone analogs for the treatment of cancer | |
| JPH0136445B2 (en) | ||
| JPH11508566A (en) | Antibacterial synergistic composition containing rifabutin | |
| US5432187A (en) | Benzimidazole anthelmintic in the treatment of microsporidial infections | |
| CN101116665B (en) | Malaria-resisting arteannuin naphthoquine compound composition | |
| CA2066134C (en) | Complexes of polyadenylic acid with polyuridylic acid | |
| US20030203045A1 (en) | Therapeutic composition for the treatment of HIV-1 and HIV-2 | |
| US4302452A (en) | Use of derivatives of 6α-methylprednisolone as an antiemetic | |
| JPS5938207B2 (en) | Kidney disease treatment | |
| EP0372676A1 (en) | Therapeutic preparation and method | |
| JPS6143114A (en) | Eye drop for remedy of iridal and ciliary disease | |
| WO1991007953A1 (en) | Tumour necrosis factor antagonist | |
| CA2167841A1 (en) | Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes | |
| JPH01313433A (en) | Anti-hiv agent | |
| CN109125256B (en) | Prednisolone injection and preparation method thereof | |
| AU629520B2 (en) | A medicament | |
| JPH06502846A (en) | Pharmaceutical composition comprising CD4 and anti-HIV polyanion agent and method for using the same | |
| US3836644A (en) | Treatment of wounds | |
| JPH0321252A (en) | Cysplatin high tension liquid | |
| JPS6357520A (en) | Antiulcer agent | |
| Weber et al. | Effect of long-term administration of metyrapone and dexamethasone in a patient with Cushing's syndrome | |
| JPH0720860B2 (en) | Anti-cancer drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20050725 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |